Journal article
+ 1 other files
Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer
-
Ciarloni, Laura
Novigenix SA, Biopôle IV, Epalinges, Switzerland
-
Ehrensberger, Sahar Hosseinian
Novigenix SA, Biopôle IV, Epalinges, Switzerland
-
Imaizumi, Natsuko
Novigenix SA, Biopôle IV, Epalinges, Switzerland
-
Monnier-Benoit, Sylvain
Novigenix SA, Biopôle IV, Epalinges, Switzerland
-
Nichita, Cristina
Service de Gastro-entérologie et d'Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
-
Myung, Seung-Jae
Department of Internal Medicine, ASAN Medical Center, Seoul, Korea
-
Kim, Joo Sung
Seoul National Univerisity, Korea
-
Song, Si Young
Internal Medicine, Yonsei University College of Medicine, Korea
-
Kim, Tae Il
Department of Internal Medicine, Yonsei University College of Medicine, Korea
-
Weg, Boudewijn van der
Gastroenterologie, Spital Thun, Switzerland
-
Meier, Rémy
Gastroenterology, Hepatology and Nutrition, Kantonsspital Liestal, Switzerland
-
Borovicka, Jan
Abt.Gastroenterologie/Hepatologie, Kantonsspital St.Gallen, Switzerland
-
Beglinger, Christoph
Department of Gastroenterology, University Hospital of Basel, Switzerland
-
Vallet, Cédric
Service de Chirurgie, Ensemble Hospitalier de la Côte, Switzerland
-
Maerten, Philippe
Internal Medicine, Clinique Cecil, Lausanne, Switzerland
-
Rüegg, Curzio
Pathology, Department of Medicine, Faculty of Sciences, University of Fribourg, Switzerland
-
Dorta, Gian
Service de Gastro-entérologie et d'Hépatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Show more…
Published in:
- Clinical Cancer Research. - 2016, vol. 22, no. 18, p. 4604-4611
English
A blood test for colorectal cancer (CRC) screening is a valuable tool to for testing asymptomatic individuals and reducing CRC-related mortality. The objective of this study was to develop and validate a novel blood test able to differentiate patients with CRC and adenomatous polyps (AP) from individuals with a negative colonoscopy. Experimental Design: A case-control, multicenter clinical study was designed to collect blood samples from patients referred for colonoscopy or surgery. Predictive algorithms were developed on 75 controls, 61 large AP (LAP) {greater than or equal to}1cm, 45 CRC, and independently validated on 74 controls, 42 LAP, 52 CRC (23 Stages I-II) as well as on 245 cases including other colorectal findings and diseases other than CRC. The test is based on a 29-gene panel expressed in peripheral blood mononuclear cells alone or in combination with established plasma tumor markers. Results: The 29-gene algorithm detected CRC and LAP with a sensitivity of 79.5% and 55.4%, respectively, with 90.0% specificity. Combination with the protein tumor markers CEA and CYFRA21-2 resulted in a specificity increase (92.2%) with a sensitivity for CRC and LAP detection of 78.1% and 52.3%, respectively. Conclusions: We report the validation of a novel blood test, Colox®, for the detection of CRC and LAP based on a 29-gene panel and the CEA and CYFRA21-1 plasma biomarkers. The performance and convenience of this routine blood test provides physicians a useful tool to test average risk individuals unwilling to undergo upfront colonoscopy.
-
Faculty
- Faculté des sciences et de médecine
-
Department
- Médecine 3ème année
-
Language
-
-
Classification
-
Biological sciences
-
License
-
License undefined
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/unifr/documents/304891
Other files
Statistics
Document views: 48
File downloads:
- rue_dcv.pdf: 62
- rue_dcv_sm.pdf: 48